Fatigue was positively correlated with the frequency, duration, severity, and chronicity of migraine episodes, as well as excessive daytime sleepiness.
Long-term benefits of Vyepti® confirmed by new data presented at the annual meeting of the American Headache SocietyAn extension phase of the DELIVER study with Vyepti® (eptinezumab) demonstrated long-lasting migraine preventive effects with treatment for up to 18 months, reducing both frequency and severity.
BOSTON — Headache-related quality of life lagged clinical improvement in headaches for individuals with long COVID at 12 to 19 months, according to a poster from the American Academy of Neurology annual meeting.“It helps to understand what the risks of long COVID are for patients who may previously suffer from headache in order to monitor and treat these patients in a way that is most